Premium
High‐dose cytosine arabinoside in previously treated patients with poor‐prognosis non‐Hodgkin's lymphoma
Author(s) -
Adelstein David J.,
Lazarus Hillard M.,
Hines John D.,
Herzig Roger H.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851001)56:7<1493::aid-cncr2820560702>3.0.co;2-m
Subject(s) - medicine , nausea , gastroenterology , vomiting , lymphoma , non hodgkin's lymphoma , chemotherapy , surgery
Fourteen previously treated patients with relapsed or refractory poor‐prognosis non‐Hodgkin's lymphoma were given chemotherapy regimens containing high doses of cytosine arabinoside alone (seven patients) or with an anthracycline or amsacrine (seven patients). Five patients achieved a complete remission and two patients had a partial remission. The durations of remission, however, were short (median, 3 months; range, 2–6 months). Toxicities included conjunctivitis, photophobia, stomatitis, dermatitis, cerebellar dysfunction, diarrhea, nausea, vomiting, liver dysfunction, and severe myelosuppression. Recovery of an absolute granulocyte count greater than 500/μl and an untransfused platelet count greater than 20.000/ μl required a median of 31 (range, 28–35) and 30 (range, 27–43) days, respectively. Six patients died with recurrent or residual disease before bone marrow recovery. Younger age, good performance status, and a previous complete remission were predictive of a good response. High‐dose cytosine arabinoside has major myelotoxicity but significant activity in some patients with poor‐prognosis non‐Hodgkin's lymphoma. Cancer 56: 1493‐1496, 1985.